Navigation Links
FDA approves MyocondaR IND for MAP in Crohn's Disease

SYDNEY, Australia 24 April 2007. Giaconda Ltd (ASX: GIA) today announced that the US Food and Drug Administration (FDA) has approved the Company's Investigational New Drug application (IND) for the clinical development of MyocondaR to treat patients with Crohn's Disease infected with Mycobacterium avium spp paratuberculosis (MAP).

The Company understands that its lead product, MyocondaR, is the first therapy to be submitted to the FDA for this indication. There are no anti-MAP therapies approved for use in Crohn's Disease.

MAP is considered as the most likely infectious cause of Crohn's Disease. Current treatments on the market are indicated for symptomatic treatment of the disease. On the basis of clinical experience, Giaconda believes that by treating and controlling the underlying MAP infection, MyocondaR will offer a valuable therapy to patients who do not respond to currently available therapies. Current research indicates that between 40 - 50% of Crohn's patients are MAP positive.

Patients can be diagnosed with MAP infection using a blood test. The IND approval allows the Company to commence the next clinical trial of MyocondaR in the USA. The Company is continuing preparations for the multi-centre, double blind, placebo controlled, Phase II/III trial. Before the trial commences the Company will conduct pharmacokinetics investigations, test the drug manufacturing for the trial and make ethics submissions to the various clinical trial centres. It is anticipated that the trial will commence by the end of 2007.

Since the previous Phase III trial, which was undertaken prior to Giaconda acquiring MyocondaR, an alternative development program, substantially different from its predecessor, has been undertaken based on further understanding of the mechanism of action of MyocondaR. This has resulted in a new product based on the original research. The Phase II/III trial is necessary due to the changes in the drug form
'"/>




Page: 1 2 3 4

Related medicine technology :

1. FDA approves IND on Lead Product M6G
2. ChemoCentryx Presents Positive Phase 2 Clinical Data for Traficet-EN in Crohns Disease at the Digestive Disease Week 2007 Conference
3. Enzo Biochem Individualized Oral Immune Regulation Therapy May Be Effective Approach to Treating Crohns Disease
4. UCB Presents Long-Term CImzia Data in Crohns Disease
5. New Analysis of Data Shows Treatment With Abbotts Humira (Adalimumab) Significantly Reduced Disease-Related Hospitalization for Patients with Crohns Disease
6. Appendicitis: Evolving Tools to Diagnose a Classic Disease
7. Non-Invasive Diagnostic Tests for Celiac Disease
8. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Samaritans Alzheimers Drug Caprospinol Suggests Brain May be Able to Heal From Alzheimers Disease
11. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: FDA approves MyocondaR IND for MAP Crohn Disease
(Date:1/15/2014)... N.J. , Jan. 15, 2014  Celsion Corporation (the "Company") ... has received commitments from institutional investors to purchase an ... stock in an at-the-market registered direct offering, led by ... entered into definitive purchase agreements with these investors pursuant ...
(Date:1/15/2014)... Shire plc (LSE: SHP, NASDAQ: SHPG ) ... approval condition to the announced tender offer for all of the ... a result of the waiver, the transaction is no longer conditional ... on January 24, 2014 following the currently scheduled expiration time, subject ...
(Date:1/15/2014)... 15, 2014 BreedIT Corp (OTC: BRDT), ... distributor of highly sophisticated agro-breeding solutions for plant breeders ... the Company,s board of directors appointed chemistry and pharmaceutical ... new member of the board. From 1975 ...
Breaking Medicine Technology:Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3
... --   Masimo (NASDAQ: MASI ... Acoustic Monitoring™, and Masimo SET ® Measure-Through Motion ... Medical Devices, Inc. dismissed all outstanding claims against Masimo ... and Cercacor.   Masimo did not incur any liability to ...
... QBC Diagnostics, a global manufacturer of hematology ... the company has been awarded a U.S. General ... Equipment and Services. GSA,s Scientific Equipment ... with scientific instruments for a wide variety of ...
Cached Medicine Technology:Essential Medical Dismisses Patent Case against Masimo and Cercacor 2Essential Medical Dismisses Patent Case against Masimo and Cercacor 3Essential Medical Dismisses Patent Case against Masimo and Cercacor 4QBC Diagnostics Awarded GSA Contract 2
(Date:4/17/2014)... pain relief targets that could be used to ... King,s College London made the discovery when researching ... of the body. , Dr Marzia Malcangio said: ... pain generation and our findings could help chemotherapy ... One potential side effect of some chemotherapy drugs ...
(Date:4/17/2014)... Diego School of Medicine report that older women, plucky ... loss are more likely to be compassionate toward strangers ... in this month,s issue of the International Journal ... associated with better health and well-being as we age, ... the outcomes of individuals whose deficits in compassion put ...
(Date:4/17/2014)... has created a new technology for modifying human ... the body and selectively target cancer and other ... that monitor and modify human physiology is a ... existing technology enabled bioengineers to build such devices ... in a customized fashion. , "The project addressed ...
(Date:4/17/2014)... NEW YORK, NY (April 16, 2014) The cause ... but a new study proposes that neurons may be ... own immune system, similar to the way autoimmune diseases ... attack the body,s cells. The study was published April ... is a new, and likely controversial, idea in Parkinson,s ...
(Date:4/17/2014)... 2014 EcoHealth Alliance, a nonprofit organization that focuses ... comprehensive review today examining the current state of knowledge ... calls for improved global surveillance strategies to combat the ... of Ebola in West Africa that has claimed the ... and Liberia. According to the World Health Organization ...
Breaking Medicine News(10 mins):Health News:New pain relief targets discovered 2Health News:The ilk of human kindness 2Health News:Building 'smart' cell-based therapies 2Health News:Is Parkinson's an autoimmune disease? 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3
... national provider of tele-health solutions, has received full accreditation from URAC ... URAC assures that SironaHealth has met all relevant standards and performs ... is timely, confidential, and includes medically appropriate care and treatment advice. ... ...
... complete medical travel packages for North American patients seeking ... ... Long Beach, Calif. (PRWEB) April 8, 2009 -- With U.S. ... trillion this year, health insurers, self-insured employers, groups and individuals are ...
... Multiple, anatomically distinct lung cancer tumors may frequently arise ... analysis of patient tumor samples published in the April ... National Cancer Institute. , Some lung cancer patients ... diagnosis. Although such multiple tumors usually share a common ...
... that the growth factor known as TGF-β is essential to ... blocking it can cause retinal dysfunction. These findings, published in ... have an important impact on the prevention and treatment of ... results are significant because they add to our understanding of ...
... testing after ,very promising, early results, , , TUESDAY, April ... radically different way of attacking prostate cancer has done ... larger-scale testing, researchers report. , One standard treatment for ... male hormones such as testosterone that help drive tumor ...
... women, not men, researchers report , , TUESDAY, April 7 ... the list of cardiac problems linked to overweight and ... however we measure it, is associated with the risk ... fellow at the Cardiovascular Epidemiology Research Unit of Beth ...
Cached Medicine News:Health News:SironaHealth Receives URAC Accreditation as a Health Call Center 2Health News:SironaHealth Receives URAC Accreditation as a Health Call Center 3Health News:Reducing Costs, Not Care: Medical Travel to New Zealand Can Help Alleviate Rising U.S. Healthcare Expenses for Insurers and Self-funded Employers 2Health News:Reducing Costs, Not Care: Medical Travel to New Zealand Can Help Alleviate Rising U.S. Healthcare Expenses for Insurers and Self-funded Employers 3Health News:Reducing Costs, Not Care: Medical Travel to New Zealand Can Help Alleviate Rising U.S. Healthcare Expenses for Insurers and Self-funded Employers 4Health News:Multifocal lung cancers appear to originate from single cancer clone 2Health News:Growth factor TGF-B helps maintain health of retinal blood vessels 2Health News:New Prostate Cancer Drug May Hold Promise 2Health News:New Prostate Cancer Drug May Hold Promise 3Health News:Obesity Linked to Heart Failure Risk 2
... Sorvall DiscoveryTMM150 SE Micro-ultra centrifuge continues to ... sample processing, now with 1,048,000 x g ... rotor. DiscoveryTMM150SE processes sample sizes from ... small floor footprint, brushless direct drive, very ...
... and environmental safety are the ... K Ultracentrifuge from Beckman Coulter. ... centrifugation technology, the LE-80 K ... provide advanced capability for your ...
... Optima L-XP ultracentrifuge is designed to ... discovery process if research involves proteomics, ... sophisticated on-board computer, enhanced firmware, powerful ... touch screen, Optima L-XP delivers superior ...
... chemistry system brings versatility in a ... laboratory. A model of innovation and ... system features state-of-the-art Dimension testing technology, ... in a flexible. affordable, easy-to-use system ...
Medicine Products: